

THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS

Abstract of the Disclosure

5 Methods are provided for inhibiting stenosis following
vascular trauma or disease in a mammalian host, comprising
administering to the host a therapeutically effective dosage
of a therapeutic conjugate containing a vascular smooth muscle
binding protein that associates in a specific manner with a
cell surface of the vascular smooth muscle cell, coupled to
10 a therapeutic agent dosage form that inhibits a cellular
activity of the muscle cell. Methods are also provided for
the direct and/or targeted delivery of therapeutic agents to
vascular smooth muscle cells that cause a dilation and
fixation of the vascular lumen by inhibiting smooth muscle
15 cell contraction, thereby constituting a biological stent.
Also discussed are mechanisms for in vivo vascular smooth
muscle cell proliferation modulation, agents that impact those
mechanisms and protocols for the use of those agents.

"Express Mail" mailing label number: EL67164114US

Date of Deposit: July 20, 2001

This paper or fee is being deposited on the date indicated above with
the United States Postal Service pursuant to 37 CFR 1.10, and is
addressed to the Commissioner for Patents, Box Patent Application,
Washington, D.C. 20231.